Bone Biologics (OTC:BBLG) Shares Down 4.7% – What’s Next?

Bone Biologics Co. (OTC:BBLG) traded down 4.7% during mid-day trading on Monday . The stock traded as low as $1.1780 and last traded at $1.22. 13,638 shares traded hands during mid-day trading, a decline of 56% from the average session volume of 30,934 shares. The stock had previously closed at $1.28.

Bone Biologics Stock Down 4.7%

The business’s 50-day moving average is $1.45 and its two-hundred day moving average is $1.85. The company has a market capitalization of $2.19 million, a P/E ratio of -0.32 and a beta of 0.78.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.